sorbitol has been researched along with Body Weight in 110 studies
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study examined the effects of hyperglycemia and treatment with the aldose reductase inhibitor, Tolrestat, on the pain behavior evoked by injection of formalin into the dorsum of a single hind paw." | 7.69 | Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. ( Calcutt, NA; Malmberg, AB; Yaksh, TL; Yamamoto, T, 1994) |
| " However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin." | 5.39 | Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. ( Balakrishna, N; Grama, CN; Kumar, MN; Patil, MA; Raghu, G; Reddy, GB; Suryanarayana, P, 2013) |
| " One of these toxic findings was cataract, and we have found that cataract appeared in rats dosed orally with FK506 for 13 weeks and more." | 5.30 | Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. ( Fukuhara, Y; Hisatomi, A; Ishida, H; Mitamura, T; Murato, K; Ohara, K; Takahashi, Y, 1997) |
| " This study intends to examine the effects of sea buckthorn and metformin on body weight, water and feed intake, glycaemia, insulinemia, sorbitol accumulation and cataract development in Zucker diabetic fatty rats, which represent an animal model of type 2 Diabetes mellitus, as well as to characterize the individual content of bioactive substances and the antioxidant activity of sea buckthorn." | 4.12 | The consumption of sea buckthorn (Hippophae rhamnoides L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats. ( Brindza, J; Capcarova, M; Dupak, R; Hrnkova, J; Ivanisova, E; Kalafova, A; Kovac, J; Prnova, MS; Schneidgenova, M; Simonova, N; Tokarova, K, 2022) |
| "Biorhythms with higher levels of activity of sorbitol dehydrogenase and lactate dehydrogenase in blood plasma, specific activity of sorbitol dehydrogenase, lactate dehydrogenase, and malate dehydrogenase in the liver, and body weight of rats were more pronounced in the spring-summer period than in the autumn-winter period." | 3.74 | Biorhythms of activities of liver and blood dehydrogenases and changes in body weight of the rats feeding normal diet or excess of sugar substitutes. ( Kichenko, SM; Petrovich, YA; Volozhin, AI; Zubtsov, VA, 2007) |
| "Studies show that the pyruvate treatment decreased the extent of several biochemical changes known to be associated with cataract formation, such as the elevation in the levels of glycated proteins, sorbitol, lipid peroxidation (MDA) and inhibition of the cation pump." | 3.70 | Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate. ( Ali, AH; Devamanoharan, PS; Henein, M; Varma, SD; Zhao, W, 2000) |
| "This study examined the effects of hyperglycemia and treatment with the aldose reductase inhibitor, Tolrestat, on the pain behavior evoked by injection of formalin into the dorsum of a single hind paw." | 3.69 | Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. ( Calcutt, NA; Malmberg, AB; Yaksh, TL; Yamamoto, T, 1994) |
| " The primary objective was to examine the dose-response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks." | 2.94 | Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. ( Keefe, D; Sano, M; Tsumiyama, I; Yokote, K, 2020) |
| "This dose-response analysis evaluated change in body weight following 24 weeks with four once-daily and twice-daily licogliflozin doses (2." | 2.94 | Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. ( Bays, HE; Keefe, D; Kozlovski, P; Proot, P; Shao, Q, 2020) |
| " Safety assessments included adverse events, laboratory tests and vital signs." | 2.87 | Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. ( Fukatsu, A; Imazeki, H; Ochiai, H; Sakai, S; Sasaki, T; Seino, Y, 2018) |
| " The safety end points included adverse events (AEs) and laboratory parameters." | 2.82 | Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. ( Fukatsu, A; Haneda, M; Inagaki, N; Kakiuchi, H; Kaku, K; Sakai, S; Samukawa, Y; Sasaki, T; Sato, Y; Seino, Y, 2016) |
| "Although patients with type 2 diabetes often have hepatic impairment, few reports have been published concerning the influence of luseogliflozin on HbA1c and hepatic function in patients with type 2 diabetes accompanied by hepatic impairment." | 2.82 | Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes. ( Kusunoki, M; Miyata, T; Natsume, Y; Oshida, Y; Sato, D; Suga, T; Tsutsui, H; Tsutsumi, K, 2016) |
| "In posthaemorrhagic and postmeningitic hydrocephalus valuable time was gained before shunt therapy until the infant and his CSF were fit for operation." | 2.64 | Isosorbide in treatment of infantile hydrocephalus. ( Lorber, J, 1975) |
| " These include the question as to when and to whom early use of SGLT2 inhibitors would be most suitable, as well as instructions on reduction of sulfonylurea dosage during add-on treatment." | 1.42 | Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time? ( Pafili, K; Papanas, N, 2015) |
| " However, low peroral bioavailability is a major limiting factor for the success of clinical utilization of curcumin." | 1.39 | Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. ( Balakrishna, N; Grama, CN; Kumar, MN; Patil, MA; Raghu, G; Reddy, GB; Suryanarayana, P, 2013) |
| "Fidarestat inhibited the increase with an IC50 value of 18 nmol/l." | 1.31 | Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes. ( Aoki, T; Makino, M; Mizuno, K; Sassa, H; Sobajima, H; Suzuki, T; Taniko, K, 2001) |
| "After 6 weeks of untreated streptozotocin diabetes, rats were treated for 2 weeks." | 1.30 | Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. ( Basso, M; Cameron, NE; Cotter, MA; Hohman, TC, 1997) |
| " One of these toxic findings was cataract, and we have found that cataract appeared in rats dosed orally with FK506 for 13 weeks and more." | 1.30 | Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. ( Fukuhara, Y; Hisatomi, A; Ishida, H; Mitamura, T; Murato, K; Ohara, K; Takahashi, Y, 1997) |
| "Methylguanidine was only approximately 7% as effective as aminoguanidine as an inhibitor of AGE formation from L-lysine and G6P; both compounds were poor inhibitors of AR." | 1.29 | Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. ( Chang, K; Corbett, JA; Currie, MG; Hasan, KS; McDaniel, ML; Misko, TP; Moore, WM; Petrash, JM; Smith, SR; Tilton, RG, 1993) |
| "At 8 months galactosemia reduced NCV to 58% of control values, while ARI-treatment for 8 months improved NCV to 71% of control values." | 1.29 | Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy. ( Basso, M; Cherian, PV; Hohman, TC; Kamijo, M; Sima, AA, 1994) |
| "Iloprost was administered intraperitoneally to streptozotocin-induced diabetic rats at a dose of 10 micrograms/kg/day for a month." | 1.28 | Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats. ( Ito, H; Kanazawa, A; Miwa, T; Ohno, A; Tanaka, A, 1992) |
| "The betaine increase compensated for the sorbitol decrease such that the total organic osmolytes maintained the same ratio to sodium contents as controls." | 1.28 | Effects on rat renal osmolytes of extended treatment with an aldose reductase inhibitor. ( Edmands, S; Yancey, PH, 1992) |
| "The results suggest overall that while riboflavin deficiency may affect certain biochemical indices, such as sorbitol and thiobarbituric-reactive substances, in the lens and other tissues, these changes are not the result of lowered glutathione levels." | 1.28 | Glutathione and related indices in rat lenses, liver and red cells during riboflavin deficiency and its correction. ( Bates, CJ, 1991) |
| "If not treated, visceral leishmaniasis is often fatal." | 1.28 | Chemotherapy of experimental visceral leishmaniasis in the opossum. ( Chapman, WL; Hanson, WL; White, MR, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (40.00) | 18.7374 |
| 1990's | 40 (36.36) | 18.2507 |
| 2000's | 13 (11.82) | 29.6817 |
| 2010's | 9 (8.18) | 24.3611 |
| 2020's | 4 (3.64) | 2.80 |
| Authors | Studies |
|---|---|
| Dupak, R | 1 |
| Hrnkova, J | 1 |
| Simonova, N | 1 |
| Kovac, J | 1 |
| Ivanisova, E | 1 |
| Kalafova, A | 1 |
| Schneidgenova, M | 1 |
| Prnova, MS | 1 |
| Brindza, J | 1 |
| Tokarova, K | 1 |
| Capcarova, M | 1 |
| Yokote, K | 1 |
| Sano, M | 1 |
| Tsumiyama, I | 1 |
| Keefe, D | 2 |
| Bays, HE | 1 |
| Kozlovski, P | 1 |
| Shao, Q | 1 |
| Proot, P | 1 |
| Jinnouchi, H | 1 |
| Yoshida, A | 1 |
| Tsuyuno, H | 1 |
| Iwamoto, K | 1 |
| Sugiyama, S | 1 |
| Hieshima, K | 1 |
| Kajiwara, K | 1 |
| Kurinami, N | 1 |
| Suzuki, T | 4 |
| Jinnouchi, K | 1 |
| Jinnouchi, T | 1 |
| Seino, Y | 3 |
| Sasaki, T | 3 |
| Fukatsu, A | 3 |
| Imazeki, H | 1 |
| Ochiai, H | 1 |
| Sakai, S | 3 |
| Kojima, N | 1 |
| Williams, JM | 1 |
| Takahashi, T | 1 |
| Miyata, N | 1 |
| Roman, RJ | 1 |
| Sakamaki, S | 1 |
| Kawanishi, E | 1 |
| Koga, Y | 1 |
| Yamamoto, Y | 1 |
| Kuriyama, C | 1 |
| Matsushita, Y | 1 |
| Ueta, K | 1 |
| Nomura, S | 1 |
| Grama, CN | 1 |
| Suryanarayana, P | 1 |
| Patil, MA | 1 |
| Raghu, G | 1 |
| Balakrishna, N | 1 |
| Kumar, MN | 1 |
| Reddy, GB | 1 |
| Pafili, K | 1 |
| Papanas, N | 1 |
| Kaku, K | 2 |
| Inagaki, N | 2 |
| Haneda, M | 2 |
| Ubukata, M | 1 |
| Samukawa, Y | 2 |
| Kakiuchi, H | 1 |
| Sato, Y | 1 |
| Kusunoki, M | 1 |
| Natsume, Y | 1 |
| Sato, D | 1 |
| Tsutsui, H | 1 |
| Miyata, T | 1 |
| Tsutsumi, K | 1 |
| Suga, T | 1 |
| Oshida, Y | 1 |
| Li, X | 1 |
| Hu, J | 1 |
| Zhang, R | 1 |
| Sun, X | 1 |
| Zhang, Q | 1 |
| Guan, X | 1 |
| Chen, J | 1 |
| Zhu, Q | 1 |
| Li, S | 1 |
| Petrovich, YA | 1 |
| Volozhin, AI | 1 |
| Zubtsov, VA | 1 |
| Kichenko, SM | 1 |
| Cheng, X | 1 |
| Ni, B | 1 |
| Zhang, Z | 1 |
| Liu, Q | 1 |
| Wang, L | 1 |
| Ding, Y | 1 |
| Hu, Y | 1 |
| VANHEYNINGEN, R | 1 |
| HOEGBERG, KG | 1 |
| LINDVALL, S | 1 |
| BRIN, M | 1 |
| Jones, LD | 1 |
| Castleberry, MW | 1 |
| Canham, JE | 1 |
| King, NW | 1 |
| Yokozawa, T | 1 |
| Yamabe, N | 1 |
| Cho, EJ | 1 |
| Nakagawa, T | 1 |
| Oowada, S | 1 |
| Li, F | 1 |
| Szabó, C | 1 |
| Pacher, P | 1 |
| Southan, GJ | 1 |
| Abatan, OI | 1 |
| Charniauskaya, T | 1 |
| Stevens, MJ | 3 |
| Obrosova, IG | 2 |
| Bernobich, E | 1 |
| Cosenzi, A | 1 |
| Campa, C | 1 |
| Zennaro, C | 1 |
| Sasso, F | 1 |
| Paoletti, S | 1 |
| Bellini, G | 1 |
| Shimada, H | 2 |
| Takahashi, M | 1 |
| Shimada, A | 1 |
| Okawara, T | 1 |
| Yasutake, A | 1 |
| Imamura, Y | 1 |
| Kiyozumi, M | 2 |
| Yono, M | 1 |
| Latifpour, J | 1 |
| Yoshida, M | 3 |
| Ueda, S | 1 |
| Lin, HJ | 1 |
| Loh, CH | 1 |
| Liao, MT | 1 |
| Liu, TT | 1 |
| Hsieh, PS | 1 |
| Frostell, G | 1 |
| Keyes, PH | 1 |
| Larson, RH | 1 |
| Bonfiglioli, D | 1 |
| Sommariva, D | 1 |
| Rovelli, L | 1 |
| Panigo, F | 1 |
| Gatti, P | 1 |
| Cialfi, A | 1 |
| Grimoldi, M | 1 |
| Cabrini, E | 1 |
| Fasoli, A | 1 |
| Grenby, TH | 1 |
| Colley, J | 1 |
| Bauchart, D | 2 |
| Gillon, KR | 1 |
| Hawthorne, JN | 1 |
| Siegel, EG | 1 |
| Trapp, VE | 1 |
| Wollheim, CB | 1 |
| Renold, AE | 1 |
| Schmidt, FH | 1 |
| Bauer, KD | 1 |
| Griminger, P | 1 |
| Hotta, N | 5 |
| Kakuta, H | 3 |
| Fukasawa, H | 3 |
| Koh, N | 5 |
| Sakakibara, F | 5 |
| Nakamura, J | 5 |
| Hamada, Y | 4 |
| Wakao, T | 2 |
| Hara, T | 5 |
| Mori, K | 3 |
| Tilton, RG | 2 |
| Chang, K | 2 |
| Hasan, KS | 1 |
| Smith, SR | 1 |
| Petrash, JM | 1 |
| Misko, TP | 1 |
| Moore, WM | 1 |
| Currie, MG | 1 |
| Corbett, JA | 1 |
| McDaniel, ML | 1 |
| Tesfamariam, B | 1 |
| Palacino, JJ | 1 |
| Weisbrod, RM | 1 |
| Cohen, RA | 1 |
| Soulis-Liparota, T | 1 |
| Cooper, ME | 1 |
| Dunlop, M | 1 |
| Jerums, G | 1 |
| Kamijo, M | 2 |
| Basso, M | 2 |
| Cherian, PV | 1 |
| Hohman, TC | 3 |
| Sima, AA | 2 |
| Calcutt, NA | 2 |
| Malmberg, AB | 1 |
| Yamamoto, T | 1 |
| Yaksh, TL | 1 |
| Yee, S | 1 |
| Fazekas-May, M | 1 |
| Walker, EM | 1 |
| Montague, D | 1 |
| Stern, S | 1 |
| Heard, KW | 1 |
| Klein, P | 1 |
| Reingruber, B | 1 |
| Lattimer, SA | 1 |
| Van Huysen, C | 2 |
| Greene, DA | 2 |
| Hidaka, S | 2 |
| Funakoshi, T | 1 |
| Tsuruoka, M | 2 |
| Kojima, S | 2 |
| Hamara, Y | 1 |
| Nakashima, E | 3 |
| Sasaki, H | 2 |
| Sakamoto, N | 2 |
| Cameron, NE | 3 |
| Cotter, MA | 3 |
| Naruse, K | 1 |
| Terril-Robb, LA | 1 |
| Clemons, DJ | 1 |
| Besch-Williford, C | 1 |
| O'Brien, DP | 1 |
| O'Dell, BL | 1 |
| Ashizawa, N | 2 |
| Sugiyama, Y | 2 |
| Akaike, N | 2 |
| Ohbayashi, S | 2 |
| Aotsuka, T | 2 |
| Abe, N | 1 |
| Fukushima, K | 1 |
| Matsuura, A | 2 |
| Ishida, H | 1 |
| Mitamura, T | 1 |
| Takahashi, Y | 1 |
| Hisatomi, A | 1 |
| Fukuhara, Y | 1 |
| Murato, K | 1 |
| Ohara, K | 1 |
| Kasama, N | 1 |
| Inukai, S | 1 |
| Shinohara, R | 1 |
| Mano, T | 1 |
| Nagasaka, A | 1 |
| Sawai, Y | 1 |
| Uchimura, K | 1 |
| Hayashi, R | 1 |
| Hayakawa, N | 1 |
| Nagata, M | 1 |
| Makino, M | 3 |
| Kakizawa, H | 1 |
| Itoh, Y | 1 |
| Nakai, A | 1 |
| Itoh, M | 1 |
| Pieper, GM | 1 |
| Lai, CS | 1 |
| Fathallah, L | 1 |
| Cao, X | 1 |
| Kato, N | 2 |
| Mizuno, K | 3 |
| Yagihashi, S | 1 |
| Zhao, W | 1 |
| Devamanoharan, PS | 1 |
| Henein, M | 1 |
| Ali, AH | 1 |
| Varma, SD | 1 |
| Sobajima, H | 1 |
| Aoki, T | 1 |
| Sassa, H | 1 |
| Taniko, K | 1 |
| Coppey, LJ | 1 |
| Gellett, JS | 1 |
| Davidson, EP | 1 |
| Dunlap, JA | 1 |
| Lund, DD | 1 |
| Salvemini, D | 1 |
| Yorek, MA | 1 |
| Carlson, GP | 1 |
| Tiscornia, OM | 1 |
| Lorber, J | 1 |
| Ohno, A | 1 |
| Kanazawa, A | 1 |
| Tanaka, A | 1 |
| Miwa, T | 1 |
| Ito, H | 1 |
| Matsubara, A | 1 |
| Nakano, K | 1 |
| Kurono, M | 1 |
| Bannai, C | 1 |
| Yamazaki, M | 1 |
| Matsushima, Y | 1 |
| Kunika, K | 1 |
| Itakura, M | 1 |
| Okuda, Y | 1 |
| Yamashita, K | 1 |
| Edmands, S | 1 |
| Yancey, PH | 1 |
| Schmolke, M | 1 |
| Schleicher, E | 1 |
| Guder, WG | 1 |
| Bates, CJ | 2 |
| Cowen, TD | 1 |
| Evans, PH | 1 |
| Cikrt, M | 1 |
| Bláha, K | 1 |
| Nerudová, J | 1 |
| Bittnerová, D | 1 |
| Jehlicková, H | 1 |
| Jones, MM | 2 |
| Sonobe, M | 2 |
| Yasuda, H | 2 |
| Hisanaga, T | 1 |
| Maeda, K | 1 |
| Yamashita, M | 2 |
| Kawabata, T | 1 |
| Kikkawa, R | 2 |
| Taniguchi, Y | 1 |
| Shigeta, Y | 2 |
| Carrington, AL | 1 |
| Ettlinger, CB | 1 |
| Tomlinson, DR | 3 |
| Sredy, J | 1 |
| Flam, BR | 1 |
| Sawicki, DR | 1 |
| Kargacin, B | 1 |
| Blanusa, M | 1 |
| Arezina, R | 1 |
| Kostial, K | 1 |
| Singh, PK | 1 |
| Jones, M | 1 |
| Kumari, K | 1 |
| Murthy, PS | 1 |
| Sahib, MK | 1 |
| Inoue, T | 1 |
| Miwa, I | 1 |
| Hirano, M | 1 |
| Kanbara, M | 1 |
| Okuda, J | 1 |
| Suzuki, K | 1 |
| Yen-Chung, H | 1 |
| Toyota, T | 1 |
| Goto, Y | 1 |
| Hirata, Y | 1 |
| Okada, K | 1 |
| Fields, M | 1 |
| Lewis, CG | 1 |
| Beal, T | 1 |
| Scholfield, D | 1 |
| Mayer, JH | 1 |
| Willars, GB | 1 |
| Townsend, J | 1 |
| Compton, AM | 1 |
| Churchill, RD | 1 |
| Craven, PA | 1 |
| DeRubertis, FR | 1 |
| Gaynes, BI | 1 |
| Watkins, JB | 1 |
| White, MR | 1 |
| Chapman, WL | 1 |
| Hanson, WL | 1 |
| Sochor, M | 1 |
| Kunjara, S | 1 |
| McLean, P | 1 |
| Kemper, C | 1 |
| Dvornik, D | 1 |
| Williamson, JR | 1 |
| Prater, C | 1 |
| Jeffrey, JR | 1 |
| Weigel, C | 1 |
| Sherman, WR | 1 |
| Eades, DM | 1 |
| Kilo, C | 2 |
| Yano, M | 1 |
| Hashimoto, F | 1 |
| Sato, M | 1 |
| Ohboshi, C | 1 |
| Hirota, M | 1 |
| Oshima, I | 1 |
| Ohe, Y | 1 |
| Shin, S | 1 |
| Shima, K | 1 |
| Hatanaka, I | 1 |
| Terada, M | 1 |
| Gale, GR | 1 |
| Atkins, LM | 1 |
| Smith, AB | 1 |
| Jones, SG | 1 |
| Basinger, MA | 1 |
| Sussman, I | 1 |
| Matschinsky, FM | 1 |
| Hämäläinen, MM | 1 |
| Potezny, N | 1 |
| McClure, J | 1 |
| Rofe, AM | 1 |
| Conyers, RA | 1 |
| MacKenzie, KM | 1 |
| Hauck, WN | 1 |
| Wheeler, AG | 1 |
| Roe, FJ | 1 |
| Aurousseau, B | 1 |
| Auclair, E | 1 |
| Rowland, N | 1 |
| Meile, MJ | 1 |
| Nicolaïdis, S | 1 |
| Principi, N | 1 |
| Reali, E | 1 |
| Rivolta, A | 1 |
| Elebute, EA | 1 |
| Hillbom, ME | 4 |
| Förster, H | 1 |
| Hoffmann, H | 1 |
| Hoos, I | 1 |
| Spivey, J | 1 |
| Johnston, ID | 1 |
| Alfin-Slater, RB | 1 |
| Wells, P | 1 |
| Aftergood, L | 1 |
| Melnick, D | 1 |
| Pikkarainen, PH | 2 |
| Jonás, P | 1 |
| Ciger, J | 1 |
| Havris, S | 1 |
| Wagner, KH | 1 |
| Wagner-Hering, E | 1 |
| Shehadeh, Z | 1 |
| Grantham, RN | 1 |
| Brecher, GA | 1 |
| Jacobson, ED | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease[NCT03320941] | Phase 2 | 126 participants (Actual) | Interventional | 2017-12-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment. (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percent Change (Number) |
|---|---|
| LIK066 2.5mg qd | -1.86 |
| LIK066 10mg qd | -2.84 |
| LIK066 25 mg qd | -3.41 |
| LIK066 50 mg qd | -3.80 |
| Placebo | 0.11 |
Plasma trough concentrations of LIK066 were measured at Week 12 after daily administrations of LIK066 (2.5, 10, 25 and 50 mg). (NCT03320941)
Timeframe: Week 12
| Intervention | ng/mL (Mean) |
|---|---|
| LIK066 2.5mg qd | 1.63 |
| LIK066 10mg qd | 4.17 |
| LIK066 25 mg qd | 12.8 |
| LIK066 50 mg qd | 26.4 |
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -3.54 | -4.40 | -2.45 |
| LIK066 2.5mg qd | -3.72 | -3.32 | -4.00 |
| LIK066 25 mg qd | -4.36 | -2.46 | -5.98 |
| LIK066 50 mg qd | -5.23 | -4.25 | -5.92 |
| Placebo | -3.12 | -4.31 | -1.93 |
FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.665 | -0.126 | -1.111 |
| LIK066 2.5mg qd | -0.334 | 0.002 | -0.606 |
| LIK066 25 mg qd | -0.747 | -0.262 | -1.145 |
| LIK066 50 mg qd | -0.986 | -0.472 | -1.377 |
| Placebo | -0.160 | -0.217 | -0.079 |
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -5.12 | -7.10 | -2.96 |
| LIK066 2.5mg qd | -4.90 | -5.79 | -4.16 |
| LIK066 25 mg qd | -6.36 | -3.58 | -8.63 |
| LIK066 50 mg qd | -6.94 | -4.17 | -9.00 |
| Placebo | -5.36 | -7.09 | -3.77 |
Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | cm (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.63 | -4.49 | -1.39 |
| LIK066 2.5mg qd | -2.47 | -2.78 | -2.22 |
| LIK066 25 mg qd | -2.65 | -2.08 | -2.90 |
| LIK066 50 mg qd | -3.11 | -2.23 | -3.88 |
| Placebo | -1.37 | -0.41 | -2.19 |
Uric acid will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | μmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -55.2 | -74.0 | -39.7 |
| LIK066 2.5mg qd | -52.6 | -74.9 | -34.1 |
| LIK066 25 mg qd | -58.4 | -69.1 | -48.4 |
| LIK066 50 mg qd | -62.0 | -72.9 | -51.6 |
| Placebo | 12.4 | 12.0 | 13.4 |
Urine albumin will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | x 10^4 mmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 0.008 | 2.030 | -1.051 |
| LIK066 2.5mg qd | -1.838 | -1.941 | -3.899 |
| LIK066 25 mg qd | -3.902 | -2.456 | -3.605 |
| LIK066 50 mg qd | -3.099 | -3.406 | -2.165 |
| Placebo | -1.282 | -3.611 | -0.174 |
Urine albumin to creatinine ratio will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mg/mmol (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.848 | 0.487 | -1.863 |
| LIK066 2.5mg qd | -0.849 | -0.553 | -1.234 |
| LIK066 25 mg qd | -2.552 | -0.771 | -4.005 |
| LIK066 50 mg qd | -1.878 | -1.018 | -2.631 |
| Placebo | -1.504 | -1.122 | -1.839 |
High sensitivity CRP will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 69.004 | 6.593 | 113.169 |
| LIK066 2.5mg qd | -48.448 | 16.582 | -89.337 |
| LIK066 25 mg qd | -24.207 | -36.745 | -18.143 |
| LIK066 50 mg qd | -55.536 | -43.562 | -71.025 |
| Placebo | -93.268 | -6.298 | -174.159 |
SFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -4.454 | -5.962 | -3.646 |
| LIK066 2.5mg qd | -6.562 | -7.745 | -5.457 |
| LIK066 25 mg qd | -7.983 | -7.234 | -8.415 |
| LIK066 50 mg qd | -5.745 | -2.127 | -8.481 |
| Placebo | -3.477 | -4.328 | -2.821 |
VFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percent (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -5.832 | -6.438 | -5.934 |
| LIK066 2.5mg qd | -4.139 | -1.532 | -6.461 |
| LIK066 25 mg qd | -9.185 | -5.977 | -12.916 |
| LIK066 50 mg qd | -11.352 | -7.333 | -14.728 |
| Placebo | -3.949 | -0.390 | -7.137 |
Fasting lipid profile (HDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.461 | 0.329 | -4.696 |
| LIK066 2.5mg qd | 1.499 | -0.519 | 2.886 |
| LIK066 25 mg qd | -5.253 | -3.279 | -6.993 |
| LIK066 50 mg qd | 0.112 | -0.147 | 0.235 |
| Placebo | -3.454 | -4.329 | -2.677 |
Fasting lipid profile (LDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.363 | -4.473 | -1.562 |
| LIK066 2.5mg qd | 0.757 | -3.065 | 3.727 |
| LIK066 25 mg qd | 0.037 | 2.579 | -1.295 |
| LIK066 50 mg qd | 4.726 | 2.128 | 6.803 |
| Placebo | -0.552 | -3.994 | 2.942 |
Fasting lipid profile (total cholesterol), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.983 | -6.017 | -1.367 |
| LIK066 2.5mg qd | -1.290 | -3.055 | 0.158 |
| LIK066 25 mg qd | 0.884 | 4.273 | -1.646 |
| LIK066 50 mg qd | 0.302 | -1.734 | 1.817 |
| Placebo | -2.244 | -3.559 | -0.671 |
Fasting lipid profile (Triglycerides (TG)), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 11.057 | -1.986 | 23.108 |
| LIK066 2.5mg qd | 1.840 | -1.153 | 1.016 |
| LIK066 25 mg qd | 43.928 | 52.284 | 34.747 |
| LIK066 50 mg qd | 5.307 | 14.061 | -0.057 |
| Placebo | 17.401 | 20.962 | 13.806 |
HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.355 | -0.184 | -0.491 |
| LIK066 2.5mg qd | -0.285 | -0.139 | -0.405 |
| LIK066 25 mg qd | -0.366 | -0.196 | -0.502 |
| LIK066 50 mg qd | -0.418 | -0.163 | -0.618 |
| Placebo | -0.079 | -0.050 | -0.093 |
The dose-response relationship for weight loss in dysglycemic participants and participants with T2DM. Percentage change from baseline in body weight at Week 12. (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | percentage change (Number) | |
|---|---|---|
| Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.95 | -2.66 |
| LIK066 2.5mg qd | -1.90 | -1.64 |
| LIK066 25 mg qd | -3.29 | -3.42 |
| LIK066 50 mg qd | -3.47 | -4.23 |
| Placebo | 0.00 | 0.10 |
The responder rates according to percentage decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 No Statistical Analysis for >=5% and >=10% was not calculated due to division by zero (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage of Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| >= 3% | >= 5% | >= 10% | >= 3% (Dysglycemic) | >= 5% (Dysglycemic) | >= 10% (Dysglycemic) | >= 3% (T2DM) | >= 5% (T2DM) | >= 10% (T2DM) | |
| LIK066 10mg qd | 55.6 | 27.8 | 0.0 | 75.0 | 62.5 | 0.0 | 40.0 | 0.00 | 0.00 |
| LIK066 2.5mg qd | 15.8 | 5.3 | 0.0 | 12.5 | 0.0 | 0.0 | 18.2 | 9.1 | 0.00 |
| LIK066 25 mg qd | 50.0 | 17.9 | 0.0 | 38.5 | 23.1 | 0.0 | 60.0 | 13.3 | 0.00 |
| LIK066 50 mg qd | 56.7 | 26.7 | 3.3 | 46.2 | 23.1 | 0.0 | 64.7 | 29.4 | 5.9 |
| Placebo | 7.1 | 0.0 | 0.0 | 7.7 | 0.0 | 0.0 | 6.7 | 0.00 | 0.00 |
1 review available for sorbitol and Body Weight
| Article | Year |
|---|---|
Value of glucose control in preventing complications of diabetes.
Topics: Adult; Animals; Blood Glucose; Blood Pressure; Blood Vessels; Body Weight; Collagen; Diabetes Compli | 1985 |
7 trials available for sorbitol and Body Weight
| Article | Year |
|---|---|
Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Topics: Adult; Anhydrides; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Human | 2020 |
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Topics: Adolescent; Adult; Aged; Anhydrides; Body Weight; Double-Blind Method; Female; Humans; Male; Middle | 2020 |
Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Comb | 2018 |
Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy | 2015 |
Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Admini | 2016 |
Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes.
Topics: Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hu | 2016 |
Isosorbide in treatment of infantile hydrocephalus.
Topics: Adolescent; Body Weight; Cerebrospinal Fluid Shunts; Clinical Trials as Topic; Diarrhea; Female; Hum | 1975 |
102 other studies available for sorbitol and Body Weight
| Article | Year |
|---|---|
The consumption of sea buckthorn (Hippophae rhamnoides L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats.
Topics: Animals; Antioxidants; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Frui | 2022 |
Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Body Weight; Diabetes Mellitus, Type 2; Glucose; Human | 2021 |
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabe | 2013 |
Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
Topics: Animals; Body Weight; CHO Cells; Cricetinae; Cricetulus; Glucose; Glucosides; Humans; Hypoglycemic A | 2013 |
Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model.
Topics: Aldehyde Reductase; Animals; Antioxidants; Biocompatible Materials; Biodegradation, Environmental; B | 2013 |
Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sodium-Glucose T | 2015 |
Urocortin ameliorates diabetic nephropathy in obese db/db mice.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cell Line; Connective Tissue Growth Factor | 2008 |
Biorhythms of activities of liver and blood dehydrogenases and changes in body weight of the rats feeding normal diet or excess of sugar substitutes.
Topics: Animals; Body Weight; Glucosephosphate Dehydrogenase; L-Iditol 2-Dehydrogenase; L-Lactate Dehydrogen | 2007 |
Polyol pathway mediates enhanced degradation of extracellular matrix via p38 MAPK activation in intervertebral disc of diabetic rats.
Topics: ADAM Proteins; Aggrecans; Aldehyde Reductase; Animals; Blood Glucose; Blotting, Western; Body Weight | 2013 |
CHANGES IN WEIGHT AND ADENOSINE TRIPHOSPHATE CONTENT IN THE LENS OF THE XYLOSE-FED RAT.
Topics: Adenosine Triphosphate; Alcohols; Body Weight; Diet; Lens, Crystalline; Metabolism; Rats; Research; | 1963 |
THE DISTRIBUTION OF PARENTERAL IRON HAEMATINICS IN NONPREGNANT, PREGNANT AND LACTATING RATS.
Topics: Animals; Blood Volume Determination; Body Weight; Breast Feeding; Citric Acid; Drug Combinations; Er | 1964 |
THE EFFECTS OF PENICILLIN, DL-PENICILLAMINE, AND D-SORBITOL ON ERYTHROCYTE TRANSKETOLASE ACTIVITY IN THIAMINE-DEFICIENT RATS.
Topics: Body Weight; Erythrocytes; International Cooperation; Metabolism; Penicillamine; Penicillins; Pharma | 1964 |
TOXICITY TESTING OF FAT EMULSIONS FOR INTRAVENOUS ADMINISTRATION.
Topics: Administration, Intravenous; Animals; Blood Cell Count; Body Weight; Cottonseed Oil; Egg Yolk; Emuls | 1965 |
A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Experiment | 2004 |
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diureti | 2004 |
Antihypertensive treatment and renal damage: amlodipine exerts protective effect through the polyol pathway.
Topics: Administration, Oral; Amlodipine; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen Type | 2004 |
Protection from spontaneous hepatocellular damage by N-benzyl-d-glucamine dithiocarbamate in Long-Evans Cinnamon rats, an animal model of Wilson's disease.
Topics: Animals; Body Weight; Chelating Agents; Copper; Disease Models, Animal; Dose-Response Relationship, | 2005 |
Age-related alterations in the biochemical and functional properties of the bladder in type 2 diabetic GK rats.
Topics: Acetylcholine; Adenosine Triphosphate; Aging; Animals; Body Weight; Carbachol; Diabetes Complication | 2005 |
Attenuation of hypertriglyceridemia-induced pressor effect in rats with fructose-induced insulin resistance.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Diet; Drug Combinations; Fructose; Heart Rate; | 2007 |
Effect of various sugars and sugar substitutes on dental caries in hamsters and rats.
Topics: Animals; Body Weight; Cariogenic Agents; Cricetinae; Dental Caries; Dental Plaque; Dietary Carbohydr | 1967 |
[Effect of sorbinicate on blood proteins and platelet aggregation in patients with coronary disease].
Topics: Adult; Body Weight; Humans; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Myocardial Infarc | 1984 |
Dental effects of xylitol compared with other carbohydrates and polyols in the diet of laboratory rats.
Topics: Animals; Body Weight; Dental Caries; Dental Plaque; Diet, Cariogenic; Dietary Carbohydrates; Female; | 1983 |
[Evolution of postprandial cholesterolemia and triglyceridemia with age in the preruminant calf; the effect of sorbitol ingestion].
Topics: Aging; Animals; Body Weight; Cattle; Cholesterol; Cholesterol Esters; Feeding Behavior; Free Radical | 1983 |
Transport of myo-inositol into endoneurial preparations of sciatic nerve from normal and streptozotocin-diabetic rats.
Topics: Adenosine Triphosphate; Animals; Biological Transport, Active; Body Weight; Diabetes Mellitus, Exper | 1983 |
Beneficial effects of low-carbohydrate--high-protein diets in long-term diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, Diabetic; Dietary Carboh | 1980 |
Effect of dietary carbohydrates and biotin level on cecal size and biotin concentration of growing chickens.
Topics: Animals; Biotin; Body Weight; Cecum; Chickens; Dextrins; Dietary Carbohydrates; Glucose; Sorbitol; S | 1980 |
Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 1995 |
Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.
Topics: Aldehyde Reductase; Amino Acid Oxidoreductases; Animals; Arginine; Benzothiazoles; Blood Pressure; B | 1993 |
Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta.
Topics: Acetylcholine; Adenosine Diphosphate; Aldehyde Reductase; Animals; Aorta; Blood Glucose; Body Weight | 1993 |
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Topics: Albuminuria; Aldehyde Reductase; Animals; Antioxidants; Blood Glucose; Body Weight; Butylated Hydrox | 1995 |
Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Axons; Body Weight; Diabetic Neuropathies; Fructose; Galactitol; Galact | 1994 |
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Topics: Aldehyde Reductase; Animals; Behavior, Animal; Body Weight; Diabetes Mellitus, Experimental; Female; | 1994 |
Inhibition of cisplatin toxicity without decreasing antitumor efficacy. Use of a dithiocarbamate.
Topics: Animals; Anorexia; Body Weight; Chelating Agents; Cisplatin; Male; Melanoma, Experimental; Mice; Mic | 1994 |
[The Longmire gastrectomy in the animal model: postoperative changes in fat resorption and the hormones cholecystokinin and secretin].
Topics: Animals; Body Weight; Cholecystokinin; Dietary Fats; Drug Combinations; Fat Emulsions, Intravenous; | 1994 |
Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 1993 |
Protective effect of N-benzyl-D-glucamine dithiocarbamate against renal toxicity in rats during repeated cis-diamminedichloroplatinum administrations.
Topics: Animals; Blood Urea Nitrogen; Body Weight; Chelating Agents; Cisplatin; Creatinine; Glutathione; Inj | 1995 |
Effects of propionyl-L-carnitine and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Body Weight; Cardiotonic Agents; Carnitine; Diabetes Mellitus, Experimental; | 1996 |
Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
Topics: Acetanilides; Aldehyde Reductase; Analysis of Variance; Animals; Arginine; Blood Glucose; Body Weigh | 1996 |
Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats.
Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Body Weight; Diabetic Neuropathies; Diphosphogl | 1995 |
Morphophysiologic characterization of peripheral neuropathy in zinc-deficient guinea pigs.
Topics: Animals; Blood Glucose; Body Weight; Brachial Plexus; Carbohydrates; Evoked Potentials, Somatosensor | 1996 |
Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; | 1996 |
Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Mellitus, Experimental; | 1997 |
Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Topics: Aldehyde Reductase; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Ex | 1997 |
Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Me | 1997 |
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Anticoagulants; Blood Glucose; Body Weight; Cil | 1997 |
Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447: minor contribution of nitric oxide.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 1998 |
Effects of thyroid hormone on the sorbitol pathway in streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Hyperthyro | 1998 |
Biological evaluation of the nitric oxide-trapping agent, N-methyl-D-glucamine dithiocarbamate-Fe2+, as a probe of nitric oxide activity released from control and diabetic rat endothelium.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Chelating Agents; Diabetes Mell | 1999 |
Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Blood Glucose; Blood Pressure; Body Weight; Cre | 2000 |
Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 2000 |
Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate.
Topics: Adenosine Triphosphate; Animals; Body Weight; Cataract; Crystallins; Diabetes Mellitus, Experimental | 2000 |
Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Topics: Age Factors; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Me | 2001 |
Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.
Topics: Acetylcholine; Animals; Blood Glucose; Blood Vessels; Body Weight; Diabetes Mellitus, Experimental; | 2001 |
Potentiation of carbon tetrachloride hepatotoxicity in rats by pretreatment with polychlorinated biphenyls.
Topics: Alanine Transaminase; Alcohol Oxidoreductases; Animals; Aspartate Aminotransferases; Body Weight; Ca | 1975 |
Human exocrine pancreatic response with different types of secretin. Influence of sex, age, and previous intraduodenal sorbitol infusion.
Topics: Adult; Age Factors; Aged; Amylases; Bicarbonates; Body Weight; Female; Humans; Male; Middle Aged; Pa | 1978 |
Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetic Neuropath | 1992 |
Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozo
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 1992 |
Amelioration of dermal lesions in streptozotocin-induced diabetic rats by aminoguanidine.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Electrophoresis, Polyacrylamid | 1992 |
Effects on rat renal osmolytes of extended treatment with an aldose reductase inhibitor.
Topics: Aldehyde Reductase; Animals; Betaine; Body Weight; Imidazoles; Imidazolidines; Kidney; Male; Osmolar | 1992 |
Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Neuropathies; Fructose; Hypoglycem | 1992 |
Renal sorbitol, myo-inositol and glycerophosphorylcholine in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Di | 1992 |
Effect of vitamin C on sorbitol in the lens of guinea-pigs made diabetic with streptozotocin.
Topics: Adenosine Triphosphate; Animals; Aqueous Humor; Ascorbic Acid; Ascorbic Acid Deficiency; Blood Gluco | 1992 |
Distribution and excretion of cadmium and nickel after simultaneous exposure and the effect of N-benzyl-D-glucamine dithiocarbamate on their biliary and urinary excretion.
Topics: Administration, Oral; Animals; Bile; Body Weight; Brain; Cadmium; Chelating Agents; Drinking; Drug I | 1992 |
Amelioration of nerve Na(+)-K(+)-ATPase activity independently of myo-inositol level by PGE1 analogue OP-1206.alpha-CD in streptozocin-induced diabetic rats.
Topics: Alprostadil; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; M | 1991 |
Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats.
Topics: Action Potentials; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Exper | 1991 |
Adenosine triphosphatase activity in sciatic nerve tissue of streptozocin-induced diabetic rats with and without high dietary sucrose: effect of aldose reductase inhibitors.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dietary Ca | 1991 |
Glutathione and related indices in rat lenses, liver and red cells during riboflavin deficiency and its correction.
Topics: Animals; Body Weight; Erythrocytes; Female; Glucose; Glutathione; Glutathione Reductase; Lens, Cryst | 1991 |
Effect of cadmium-mobilizing dithiocarbamates on essential trace metal metabolism in rats.
Topics: Animals; Body Weight; Cadmium; Chelating Agents; Female; Kidney; Liver; Rats; Sorbitol; Spin Labels; | 1991 |
Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycos | 1991 |
Protection against cis-diamminedichloroplatinum-induced nephrotoxicity in rats by N-benzyl-D-glucamine dithiocarbamate.
Topics: Animals; Aspartate Aminotransferases; Blood Urea Nitrogen; Body Weight; Carcinoma 256, Walker; Cispl | 1991 |
In vivo activities of aldose reductase inhibitors having a 1-(arylsulfonyl)hydantoin structure.
Topics: Aldehyde Reductase; Animals; Body Weight; Cataract; Diabetes Mellitus, Experimental; Galactosemias; | 1990 |
The significance of nerve sugar levels for the peripheral nerve impairment of spontaneously diabetic GK (Goto-Kakizaki) rats.
Topics: Aging; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Fructose; Glucose; Inos | 1990 |
Copper deficiency in pregnancy: effect on maternal and fetal polyol metabolites.
Topics: Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Carbohydrates; Catecholamines; Copper; | 1990 |
Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol.
Topics: Administration, Oral; Animals; Axonal Transport; Blood Glucose; Body Weight; Diabetes Mellitus, Expe | 1985 |
Studies on peripheral nerve and lens in long-term experimental diabetes: effects of the aldose reductase inhibitor statil.
Topics: Aldehyde Reductase; Animals; Axonal Transport; Body Weight; Carbohydrates; Choline O-Acetyltransfera | 1988 |
Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat.
Topics: 6-Ketoprostaglandin F1 alpha; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mell | 1989 |
Carbon tetrachloride and the sorbitol pathway in the diabetic mouse.
Topics: Animals; Blood Glucose; Body Weight; Carbon Tetrachloride; Diabetes Mellitus, Experimental; Fructose | 1989 |
Chemotherapy of experimental visceral leishmaniasis in the opossum.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Body Weight; Female; Leishmaniasis, Visceral; Liver; | 1989 |
The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Glucose; Glucuronates; Kidney; Lactates; Orga | 1988 |
Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glucose; I | 1986 |
Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration.
Topics: Aldehyde Reductase; Animals; Aorta; Blood Glucose; Body Weight; Capillary Permeability; Castration; | 1987 |
Specific radioimmunoassay of glucitol-lysine--application to lens proteins in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Crystallins; Diabetes Mellitus, Experimental; Lysine; Male; Rad | 1988 |
Methylcobalamin improves nerve conduction in streptozotocin-diabetic rats without affecting sorbitol and myo-inositol contents of sciatic nerve.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; Neural Conduct | 1988 |
N-alkyl-N-dithiocarboxy-D-glucamine analogs as cadmium antagonists: synthesis and evaluation of the n-propyl, n-butyl, and n-amyl derivatives.
Topics: Animals; Body Weight; Cadmium; Chemical Phenomena; Chemistry; Chemistry, Physical; Dose-Response Rel | 1988 |
Diabetes affects sorbitol and myo-inositol levels of neuroectodermal tissue during embryogenesis in rat.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Body Weight; Creatine; Diabetes Mellitus, Ex | 1988 |
Organic aciduria in rats fed high amounts of xylitol or sorbitol.
Topics: Animals; Body Weight; Citrates; Citric Acid; Cytoplasm; Gas Chromatography-Mass Spectrometry; Hydrog | 1987 |
The long-term effect of dietary administration of refined sugars and sugar alcohols on plasma biochemistry, urine biochemistry and tissue histology in mice given a limited degree of dietary self-selection.
Topics: Animals; Blood Chemical Analysis; Body Weight; Creatinine; Dietary Carbohydrates; Eating; Energy Int | 1986 |
Three-generation reproduction study of rats ingesting up to 10% sorbitol in the diet--and a brief review of the toxicological status of sorbitol.
Topics: Adrenal Medulla; Animals; Body Weight; Calcium; Diet; Eating; Female; Fertility; Liver; Male; Organ | 1986 |
Addition of sorbitol to a milk substitute for veal calves. I. Effects on health, growth and feed conversion.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Cattle; Dietary Fats; Dietary Prot | 1985 |
[Effect of various nutritive intravenous perfusions on the oral intake in the rat].
Topics: Administration, Oral; Amino Acids; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; | 1973 |
Sorbitol in total parenteral nutrition in pediatric patients.
Topics: Acute Disease; Body Weight; Child; Child, Preschool; Chromatography, Gas; Dietary Carbohydrates; Diu | 1973 |
The effects of intravenous protein--calorie supplementation on the tissue composition of postoperative body weight loss.
Topics: Adult; Amino Acids; Body Weight; Energy Metabolism; Evaluation Studies as Topic; Glucose; Humans; Ma | 1974 |
Metabolism of sorbitol modified by ethanol in rats fed with a choline-deficient or choline-supplemented low-protein high-fat diet.
Topics: Animals; Body Weight; Choline; Cytoplasm; Depression, Chemical; Dietary Fats; Dietary Proteins; Etha | 1971 |
[Metabolic effects of various carbohydrates and their significance for infusion therapy].
Topics: Alanine Transaminase; Animals; Bilirubin; Blood Glucose; Body Weight; Carbohydrate Metabolism; Fruct | 1973 |
The effect of environmental temperature and nutritional intake on the metabolic response to abdominal surgery.
Topics: Abdomen; Adult; Body Weight; Caseins; Creatinine; Diet; Energy Metabolism; Environment; Gastrectomy; | 1972 |
Safety of nuts heat-processed in molten hexitols.
Topics: Animal Nutritional Physiological Phenomena; Animals; Arachis; Body Weight; Cholesterol; Cooking; Eva | 1973 |
Rates of elimination of sorbitol and ethanol in the choline-deficient fatty liver.
Topics: Alcohol Oxidoreductases; Animals; Body Weight; Choline Deficiency; Diet; Dietary Fats; Ethanol; Fatt | 1971 |
[Use of sorbitol in edema resistant to diuretic therapy].
Topics: Body Weight; Diarrhea; Diuresis; Edema; Female; Humans; Osmolar Concentration; Sorbitol; Water-Elect | 1971 |
Inhibition of sorbitol oxidation by ethanol in intact rats pretreated with triiodothyronine or propyl thiouracil.
Topics: Animals; Body Weight; Ethanol; Hyperthyroidism; Hypothyroidism; Liver; Male; Organ Size; Oxidation-R | 1970 |
Liver alcohol and sorbitol dehydrogenase activities in hypo- and hyperthyroid rats.
Topics: Alcohol Drinking; Alcohol Oxidoreductases; Animals; Body Weight; Depression, Chemical; Diet; Ethanol | 1970 |
[Vitamin B1 metabolism and sorbitol].
Topics: Animals; Body Weight; Bradycardia; Furans; Heart Rate; Liver Glycogen; Pyrimidines; Rats; Sorbitol; | 1967 |
Effects of infusion rate and osmolarity on volumogenic diarrhea.
Topics: Animals; Body Weight; Diarrhea; Dogs; Hypertonic Solutions; Isotonic Solutions; Osmolar Concentratio | 1969 |